Literature DB >> 17602991

Epidemiology of chronic musculoskeletal pain.

John McBeth1, Kelly Jones.   

Abstract

The rate of musculoskeletal pain in adolescent and adult populations is examined, with a focus on three commonly reported pain disorders: shoulder pain, low back pain and fibromyalgia/chronic widespread pain. There is a paucity of data on musculoskeletal pain in adolescent populations. Those studies available suggest that pain is common, although the actual rates are unclear. This is probably due to differences in study methodologies and populations. Pain is commonly reported among adult populations, with almost one fifth reporting widespread pain, one third shoulder pain, and up to one half reporting low back pain in a 1-month period. The prevalence of pain varies within specific population subgroups; group factors (including socioeconomic status, ethnicity and race) and individual factors (smoking, diet, and psychological status) are all associated with the reporting of musculoskeletal pain. However, the precise nature of these relationships, and particularly the mechanisms of association, are unclear and require further investigation.

Entities:  

Mesh:

Year:  2007        PMID: 17602991     DOI: 10.1016/j.berh.2007.03.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  156 in total

1.  Prevalence of chronic widespread pain and fibromyalgia syndrome: a Korean hospital-based study.

Authors:  Cheolhwan Kim; Hyejin Kim; Jongkwan Kim
Journal:  Rheumatol Int       Date:  2011-11-06       Impact factor: 2.631

Review 2.  Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria.

Authors:  John McBeth; Matthew R Mulvey
Journal:  Nat Rev Rheumatol       Date:  2012-01-24       Impact factor: 20.543

3.  Research Consortium Workshop III to advance the Canadian Chiropractic Research Agenda.

Authors:  Kent Stuber; André Bussières; Allan Gotlib
Journal:  J Can Chiropr Assoc       Date:  2009-03

4.  The Clinical Practice Guideline Initiative: A joint collaboration designed to improve the quality of care delivered by doctors of chiropractic.

Authors:  André Bussières; Kent Stuber
Journal:  J Can Chiropr Assoc       Date:  2013-12

5.  Prevalence and Correlates of Low Pain Interference Among Patients With High Pain Intensity Who Are Prescribed Long-Term Opioid Therapy.

Authors:  Melissa H Adams; Steven K Dobscha; Ning X Smith; Bobbi Jo Yarborough; Richard A Deyo; Benjamin J Morasco
Journal:  J Pain       Date:  2018-04-27       Impact factor: 5.820

6.  Knee Pain and Structural Damage as Risk Factors for Incident Widespread Pain: Data From the Multicenter Osteoarthritis Study.

Authors:  Lisa C Carlesso; Neil A Segal; Jeffrey R Curtis; Barton L Wise; Laura Frey Law; Michael Nevitt; Tuhina Neogi
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-05-08       Impact factor: 4.794

7.  Duhuo Jisheng Decoction inhibits SDF-1-induced inflammation and matrix degradation in human degenerative nucleus pulposus cells in vitro through the CXCR4/NF-κB pathway.

Authors:  Zong-Chao Liu; Zhen-Long Wang; Chen-Yi Huang; Zhi-Jiang Fu; Yong Liu; Zhang-Chao Wei; Shi-Gui Liu; Chuan Ma; Jie-Liang Shen; Dayue Darrel Duan
Journal:  Acta Pharmacol Sin       Date:  2018-05-24       Impact factor: 6.150

Review 8.  Understanding fibromyalgia: lessons from the broader pain research community.

Authors:  David A Williams; Daniel J Clauw
Journal:  J Pain       Date:  2009-08       Impact factor: 5.820

9.  Assessing the affective load in the narratives of women suffering from fibromyalgia: the clinicians' appraisal.

Authors:  Christine Cedraschi; Elodie Girard; Valérie Piguet; Jules Desmeules; Anne-Françoise Allaz
Journal:  Health Expect       Date:  2014-12-10       Impact factor: 3.377

10.  Experimental pain responses support peripheral and central sensitization in patients with unilateral shoulder pain.

Authors:  Rogelio A Coronado; Corey B Simon; Carolina Valencia; Steven Z George
Journal:  Clin J Pain       Date:  2014-02       Impact factor: 3.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.